List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
Antag Therapeutics ApS
Carmot Therapeutics Inc
Eli Lilly and Co
Hanmi Pharmaceuticals Co Ltd
Longevity Biotech Inc
Novo Nordisk AS
Sanofi
Zealand Pharma AS
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-9423 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-441255 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GIPR and GLP1R for NASH and NAFLD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GIPR and GLP1R for Unspecified Indications - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR for Alzheimer’s Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPDI-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPI-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2019: Lilly’s tirzepatide demonstrates benefits in data presented at the American Diabetes Associations 79 Scientific Sessions
May 29, 2019: Lilly announces webcast to discuss on tirzepatide at the American Diabetes Association’s 79th Scientific Sessions
Dec 19, 2018: Carmot Therapeutics initiates phase 1 trial to treat type 2 diabetes
Oct 05, 2018: Lilly reports positive results for GIP/GLP-1 RA in type 2 diabetes trial
Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting
Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Antag Therapeutics ApS, H2 2019
Pipeline by Carmot Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Pipeline by Longevity Biotech Inc, H2 2019
Pipeline by Novo Nordisk AS, H2 2019
Pipeline by Sanofi, H2 2019
Pipeline by Zealand Pharma AS, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Companies Mentioned
• Antag Therapeutics ApS
• Carmot Therapeutics Inc
• Eli Lilly and Co
• Hanmi Pharmaceuticals Co Ltd
• Longevity Biotech Inc
• Novo Nordisk AS
• Sanofi
• Zealand Pharma AS